Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ResMedASX:RMD -2.13%94 Shiller PE Ratio is 34.16 as of Sep. 10, 2026, which is 34% below its 10-year median of 51.56. GuruFocus rates ASX:RMD with a GF Score™ of 94/100 and a GF Value™ of A$37.99 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 311 Medical Devices & Instruments companies, ResMed ranks worse than 71.7% on this metric.
As of today (2026-09-10), ResMed's current share price is A$30.74. ResMed's E10 for the quarter that ended in Jun. 2026 was A$0.90. ResMed's Shiller PE Ratio for today is 34.16.
The historical rank and industry rank for ResMed's Shiller PE Ratio or its related term are showing as below:
ASX:RMD'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 32.22 Med: 51.56 Max: 102.35
Current: 36.46
During the past years, ResMed's highest Shiller PE Ratio was 102.35. The lowest was 32.22. And the median was 51.56.
ASX:RMD's Shiller PE Ratio is ranked worse than 71.7% of 311
companies
in the Medical Devices & Instruments industry
Industry Median: 26.14
vs ASX:RMD: 36.46
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
ResMed's adjusted earnings per share data for the three months ended in Jun. 2026 was A$0.376. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is A$0.90 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
ResMed Shiller PE Ratio Related Terms
ResMed Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for ResMed's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RMD vs MDLN, WST, BDX: Shiller PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Shiller PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where ResMed's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
ResMed's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, ResMed's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
ResMed (ASX:RMD) has a Shiller PE Ratio of 34.16 as of Sep. 10, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on ResMed and its competitors. This is 34% below median its historical median of 51.56. Over the past decade, ResMed's Shiller PE Ratio has ranged from 32.22 to 102.35. According to the industry distribution chart, ResMed ranks #223 out of 311 companies in the Medical Devices & Instruments industry, placing it in the top 71.7%.
Is ResMed's Shiller PE Ratio too high?
ResMed's current Shiller PE Ratio of 34.16 is 34% below median its 10-year median of 51.56. Over the past 10 years, this metric has ranged from a low of 32.22 to a high of 102.35. The Medical Devices & Instruments industry median Shiller PE Ratio is 26.14. ResMed's value of 34.16 is 30.7% above this industry median. Based on the distribution chart, ResMed ranks #223 out of 311 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ResMed has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Shiller PE Ratio compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #223 out of 311 companies for Shiller PE Ratio. This places ResMed in the lower half of its industry. The industry median Shiller PE Ratio is 26.14. ResMed's value of 34.16 is 30.7% above this benchmark. Historically, ResMed's own Shiller PE Ratio has ranged from 32.22 to 102.35 over the past decade. While the company's 10-year median is 51.56 vs. the industry median of 26.14, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Medical Devices & Instruments company?
The median Shiller PE Ratio among Medical Devices & Instruments companies is 26.14, based on 311 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Shiller PE Ratio of 34.16 is 30.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Shiller PE Ratio is 26.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Shiller PE Ratio is 34.16, which is 34% below median its own 10-year median of 51.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$37.99, compared to a current price of A$30.74 — trading 19.1% below its estimated fair value. The current Shiller PE Ratio is 34.16, which is 34% below median its 10-year median of 51.56 and 30.7% above the Medical Devices & Instruments industry median of 26.14. ResMed's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Shiller PE Ratio is 34.16 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (ASX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of A$30.74 is trading 19.1% below its estimated GF Value™ of A$37.99.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for ASX:RMD:
Shiller PE Ratio: 34.16 (34% below median its 10-year median of 51.56)
GF Value™: A$37.99 vs. price of A$30.74 (19.1% below fair value)
Industry Position: 30.7% above the Medical Devices & Instruments median (#223 of 311)
No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
94GF Score
Get the complete analysis for ASX:RMD
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RMD has been successfully added to your 
